Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ADHD
Pharma
DEA raises production quota on Takeda's Vyvanse and its generics
With a shortage of ADHD drugs persisting, the DEA has raised production limits on Takeda’s Vyvanse and its generic versions by 24%, the agency said.
Kevin Dunleavy
Sep 4, 2024 3:24pm
Dr. Reddy's hit with ban from China's drug procurement program
Sep 3, 2024 3:56pm
FDA approves Tris Pharma's daily nighttime ADHD therapy
May 29, 2024 3:30pm
Teva's Adderall back in stock
May 22, 2024 5:44pm
Texas accuses Pfizer, Tris of providing compromised ADHD meds
Nov 21, 2023 1:21pm
Amid ADHD med shortage, AAM spotlights government restrictions
Nov 20, 2023 11:29am
